Psychiatric drug prescribing in elderly Australians: Time for action

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 9, 2011, Pages 705-708

  Hollingworth, Samantha A ^a   Lie, David C ^a,b   Siskind, Dan J ^a,b   Byrne, Gerard J ^a   Hall, Wayne D ^c   Whiteford, Harvey A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ANXIOLYTIC, SEDATIVE HYPNOTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; OXAZEPAM; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANXIETY DISORDER; AUSTRALIA; COGNITIVE DEFECT; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DEFINED DAILY DOSE; DELIRIUM; DEMENTIA; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG USE; ELDERLY CARE; FALL RISK; FALLING; FEMUR FRACTURE; HUMAN; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PREVALENCE; RESIDENTIAL AGED CARE FACILITY; RESIDENTIAL CARE; REVIEW; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS;

EID: 80052430363     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2011.594947     Document Type: Review

References (23)

1. Hollingworth SA, Burgess PM, Whiteford HA. Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry 2010; 44:513-519.
2. Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf 2010; 19:280-288.
3. Hollingworth SA, Siskind DJ, Nissen LM, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia 2002-2007. Aust N Z J Psychiatry 2010; 44:372-377.
4. Caughey GE, Ramsay EN, Vitry AI et al. Comorbid chronic diseases, discordant impact on mortality in the elderly; a 14 year longitudinal population study. J Epidemiol Community Health 2010; 64:1036-1042.
5. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. Geneva: WHO, 2008.
6. Snowdon J, Day S, Baker W. Why and how antipsychotic drugs are used in 40 Sydney nursing homes. Int J Geriatr Psychiatry 2005; 20:1146-1152.
7. Westbury JL, Jackson S, Peterson GM. Psycholeptic use in aged care homes in Tasmania, Australia. J Clin Pharm Ther 2010; 35:189-193.
8. Snowdon J, Galanos D, Vaswani D. Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. Int Psychogeriatr 2011:1-6. (Epub ahead of print; DOI: 10.1017/S1041610211000445)
9. Lie D. Mental health issues in Australian nursing homes. Aust Fam Physician 2003; 32:519-522.
10. Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr 2010; 22:1025-1039.
11. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006; 7:492-500.
12. Burke AD, Tariot PN. Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. Expert Opin Pharmacother 2009; 10:2407-2414.
13. Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging 2009; 26:381-394.
14. Huybrechts K, Rothman K, Silliman R, Brookhart A, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. Can Med Ass J 2011; 183(7):E411-E419.
15. Klink ME, Quan SF, Kaltenborn WT, Lebowitz MD. Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia. Arch Intern Med 1992; 152:1634-1637.
16. Lagnaoui R, Moore N, Moride Y, Miremont-Salame G, Begaud B. Benzodiazepine utilization patterns in Alzheimer's disease patients. Pharmacoepidemiol Drug Saf 2003; 12:511-515.
17. Pariente A, Dartigues J F, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008; 25:61-70
18. Steering Committee for the Review of Government Service Provision 2010. Report on Government Services 2010. Canberra: Productivity Commission, 2010:Table 12A.28.
19. Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Determinants of antipsychotic medication use among older people living in aged care homes in Australia. Int J Geriatr Psychiatry 2010; 25: 449-457.
20. Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsy-chotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8:151-157.
21. Westbury J, Jackson S, Gee P, Peterson G. An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. Int Psychogeriatr 2010; 22:26-36.
22. Banerjee S. The use of antipsychotic medication for people with dementia:time for action. An independent report commissioned and funded by the Department of Health. London: Department of Health, 2009.
23. Chenoweth L, King MT, Jeon YH et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol 2009; 8:317-325.